Podcast appearances and mentions of robert langreth

For something that is only used once a week, a new study finds that the popular weight-loss drug, Ozempic, could be manufactured for much less that what is being put out there.  Researchers say the weight-loss drug could be profitably produced for less than $5 dollars a month rather than the nearly $1,000 dollars Novo Nordisk charges the US.  For more, KCBS Radio's Nikki Medoro spoke with Bloomberg's Robert Langreth.   

The Supreme Court agreed this week to hear its first major case on abortion since overturning Roe v. Wade — one that could restrict the availability of the abortion pill mifepristone, even in states where abortion remains legal. Meanwhile, on Capitol Hill, lawmakers in the House and Senate finally moved to renew health programs that expired in October — but it's likely too late to finish the job in 2023. Alice Miranda Ollstein of Politico, Riley Griffin of Bloomberg News, and Lauren Weber of The Washington Post join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Jen Golbeck, a University of Maryland professor and social media superstar, about her new book, “The Purest Bond,” which lays out the science of the human-canine relationship. Plus, for “extra credit,” the panelists suggest health policy stories they read this week that they think you should read, too: Julie Rovner: The Washington Post's “They Watched Their Husbands Win the Heisman — Then Lost Them to CTE,” by Kent Babb. Alice Miranda Ollstein: Politico's “A Deadly Delivery Highlights ‘Falsified' Heat Records at USPS,” by Ariel Wittenberg. Lauren Weber: The Washington Post's “Applesauce Lead Cases in Kids Surge Amid Questions on FDA Oversight,” by Amanda Morris, Teddy Amenabar, Laura Reiley, and Jenna Portnoy. Riley Griffin: Bloomberg News' “The Next Blockbuster Drug Might Be Made in Space,” by Robert Langreth. Hosted on Acast. See acast.com/privacy for more information.

Several pharmaceutical companies are testing out whether manufacturing drugs in outer space can lead to new and improved products. For more on this, KCBS Radio's Holly Quan spoke to Bloomberg's Robert Langreth about how creating drugs in space is different in today's Tech and Business Report.

Pharmaceutical companies and insurance providers are at odds over a new class of drugs that have proven quite effective at helping people living with obesity lose weight. Bloomberg's Robert Langreth and Emma Court join this episode to share their reporting on recent advancements in weight loss treatments–and the fight over who should pay for them. And Dr. Angela Fitch, a physician and president of the Obesity Medical Association, talks about the challenges of treating obesity. Read their reporting here: Good Luck Paying for Those $10,000 Obesity Drugs Everyone's Talking About Listen to The Big Take podcast every weekday and subscribe to our daily newsletter: https://bloom.bg/3F3EJAK  Have questions or comments for Wes and the team? Reach us at bigtake@bloomberg.net.See omnystudio.com/listener for privacy information.

Bloomberg News Senior Executive Editor of Global Tech Brad Stone reports on Amazon earnings results beating estimates across the board. Bloomberg News Technology Reporter Alex Barinka on breaks down Snap earnings. Bloomberg News Health Care Reporters Emma Court and Robert Langreth discuss their Businessweek Magazine cover story Insurers Leave Patients to Pay $10,000 a Year for Obesity Drugs. And We Drive to the Close with Shaniel Ramjee, Senior Investment Manager at Pictet Asset. Hosts: Carol Massar and Madison Mills. Producer: Paul Brennan. See omnystudio.com/listener for privacy information.

Bloomberg News Senior Executive Editor of Global Tech Brad Stone reports on Amazon earnings results beating estimates across the board. Bloomberg News Technology Reporter Alex Barinka on breaks down Snap earnings. Bloomberg News Health Care Reporters Emma Court and Robert Langreth discuss their Businessweek Magazine cover story Insurers Leave Patients to Pay $10,000 a Year for Obesity Drugs. And We Drive to the Close with Shaniel Ramjee, Senior Investment Manager at Pictet Asset. Hosts: Carol Massar and Madison Mills. Producer: Paul Brennan. See omnystudio.com/listener for privacy information.

For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig's Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon and especially insidious form of ALS that runs in families. Patients are urging the US Food and Drug Administration to speed access to the drug, which hasn't yet been approved because clinical trials didn't conclusively show it works. As pharmaceutical companies use new technologies to seek cures of all kinds, this tension between making sure drugs are effective and safe, and offering not-quite-ready but possibly life-saving treatment to people for whom it's now or never, is becoming more acute. Bloomberg's chief medical writer Robert Langreth joins this episode to talk about the race to find a treatment for ALS–and the back and forth between patients, companies and government regulators. We also hear the story of a Pennsylvania family that has passed on a gene for ALS from generation to generation–and their demands for access to the new treatment. Learn more about the episode here: https://bloom.bg/3WIkvCm  Listen to The Big Take podcast every weekday and subscribe to our daily newsletter: https://bloom.bg/3F3EJAK  Have questions or comments for Wes and the team? Reach us at bigtake@bloomberg.net.See omnystudio.com/listener for privacy information.

Messenger RNA technology made it possible for scientists and drugmakers to quickly develop a Covid-19 vaccine. Now, pharmaceutical companies are racing to use mRNA for other illnesses, including flu, cancer and rare genetic diseases.  Dr. Drew Weissman, one of the researchers who pioneered the mRNA technology that led to the Covid vaccine, joins this episode to talk about his discovery, and the impact it will continue to have on the way patients are treated. Bloomberg's biosecurity reporter Riley Griffin stops in to discuss Pfizer's next phase of developing mRNA vaccines. And Bloomberg's chief medical writer Robert Langreth forecasts how this technology could transform treatment for a variety of illnesses. Learn more about this story here: https://bloom.bg/3fm3Bt8 Listen to The Big Take podcast every weekday and subscribe to our daily newsletter: https://bloom.bg/3F3EJAK  Have questions or comments for Wes and the team? Reach us at bigtake@bloomberg.net.See omnystudio.com/listener for privacy information.

We got some very good news from a late-stage clinical trial for a drug that slowed down the progression of Alzheimer's.  Biogen and Eisai's drug slowed down the cognitive decline in participants by 27% compared to those that received placebos.  The drug does not restore mental capacity or totally stop it, but works by clearing out the buildup of amyloid, a toxic protein that affects the brain.  Robert Langreth, science and health reporter at Bloomberg News, joins us for what to know.   Next, the big space news from Monday was NASA's successful DART mission, the first planetary defense test.  For this test NASA flew an unmanned spacecraft right into a asteroid to test if the impact could disrupt its orbit.  It will still take some weeks for more complete data, but for now, it worked and made for some very compelling video as it made impact.  Miriam Kramer, space reporter at Axios, joins us for more.   Finally, when Covid-19 vaccines were first rolled out, many women were complaining about a strange side effect.  They said it was messing with their menstrual cycles.  Turns out, it was true.  In a study of nearly 20,000 people and with data from a popular period-tracking app, researchers found out that on average vaccinated women experienced a one-day delay in getting their periods, but it was only temporary.  Amanda Morris, disability reporter at The Washington Post, joins us for what the research says.See omnystudio.com/listener for privacy information.

While the science is still in its early stages, the hardest part about developing a super-vaccine for all coronaviruses could be finding a way to pay for it.Bloomberg Businessweek's Mark Leydorf reads, "The Hunt for a Single Shot to Defeat Omicron and All Coronaviruses" by Robert Langreth. Learn more about your ad-choices at https://www.iheartpodcastnetwork.comSee omnystudio.com/listener for privacy information.

Robert Langreth, Healthcare Reporter for Bloomberg News, discusses his Big Take story: "Covid Delivers an Unsettling Reality Check to the World." Lynn Franco, Director of Economic Indicators and Surveys at the Conference Board, talks about the latest CCI data. William Cai, Co-Founder and Partner of Wilshire Phoenix, discusses the commodity market. Allison Poliniak-Cusic, Director of Equity Research, Transportation and Industrial Technology for Wells Fargo Securities, talks UPS earnings. Hosted by Paul Sweeney and Matt Miller. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Bloomberg's Renita Young reads "Many New mRNA Applications." This story, by Robert Langreth for Bloomberg Businessweek, explains how Moderna plans to use its mRNA technology to develop shots for influenza, HIV, Zika—and maybe even cancer. Learn more about your ad-choices at https://www.iheartpodcastnetwork.comSee omnystudio.com/listener for privacy information.

 "Many New mRNA Applications." This story, by Robert Langreth for Bloomberg Businessweek, explains how Moderna plans to use its mRNA technology to develop shots for influenza, HIV, Zika—and maybe even cancer. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

 "Many New mRNA Applications." This story, by Robert Langreth for Bloomberg Businessweek, explains how Moderna plans to use its mRNA technology to develop shots for influenza, HIV, Zika—and maybe even cancer. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Bloomberg's Renita Young reads "Many New mRNA Applications." This story, by Robert Langreth for Bloomberg Businessweek, explains how Moderna plans to use its mRNA technology to develop shots for influenza, HIV, Zika—and maybe even cancer. See omnystudio.com/listener for privacy information.

Hosts Guy Johnson and Alix Steel speak with Robert Langreth, Bloomberg Senior Health Reporter, and Ira Jersey Bloomberg Intelligence Chief U.S. Interest Rate Strategist. Plus, we hear from Albert Bourla, chief executive officer of Pfizer Inc.

Recorded June 13, 2021Current Episodes athttps://walkinverse.buzzsprout.com/I am moving all podcast here slowly. I will keep buzzsprout for all public reports and here for member only content.Report #42, "Meet Moderna: Taxpayer Funded, DARPA Approved."In this report we will look at the origin of Moderna and their connection to the Military's advanced research program funded by American taxpayers. Grab a pen and notebook and enjoy the report.* e-book report, “Meet Moderna.”Paid subscribers can download any report or e-book from the library, and gain access to all premium content. Also join me on telegram for other interesting updates. Every subscription allows me to continue fight in sharing the truth and helps me support my family. Thank you.WIV Reports — Uncensored is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.ReferencesRaul Diego. 2020. “A DARPA-Funded Implantable Biochip to Detect COVID-19 Could Hit Markets by 2021.” MintPress News (blog). September 17, 2020.Speights, Keith. 2020. “How Much Money Will Moderna Make From Its COVID Vaccine?” The Motley Fool. December 10, 2020.Robert Langreth and Naomi Kresge. 2020. “Moderna Wants to Transform the Body Into Vaccine-Making Machine.” Bloomberg.Com, August 11, 2020.WSKG. 2021. “CRISPR Scientist's Biography Explores Ethics Of Rewriting The Code Of Life.” WSKGWSKG. March 8, 2021.Max McNabb. 2021. “Doctor Testifies on COVID Vaccine Dangers to Texas Senate Committee.” Authentic Texan (blog). May 14, 2021.Angus Liu. 2021. “Moderna Lures Novartis' Top Lawyer to Be Its Own as COVID-19 Vaccine Rollout Raises Legal Risks.” FiercePharma. March 8, 2021.Ramola D. 2021. “BREAKING: Moderna COVID Vaccine Found to Contain a DEADLY POISON ‘SM-102 – Not for Human or Veterinary Use, Acutely Toxic, Fatal in Contact with Skin, Carcinogenic, Causes Infertility, Causes Nerve, Liver, Kidney Damage.'” The EveryDay Concerned Citizen. May 18, 2021.Kira Peikoff. 2018. “3 Futuristic Biotech Programs the U.S. Government Is Funding Right Now.” Leaps. October 31, 2018.Franz Walker. 2020. “DARPA Funded Implantable Biochip Can Potentially Be Used to Deploy Moderna's MRNA Vaccine.” Nanotechnology News. October 12, 2020.Patrick Tucker. 2020. “A Military-Funded Biosensor Could Be the Future of Pandemic Detection.” Defense One. March 3, 2020.Dr. Eric Van Gieson. n.d. “Epigenetic Characterization and Observation.” DARPA. Accessed April 28, 2021.DHS. 2018. “WMD Detection, Epigenome, DARPA.” Homeland Security News Wire. February 9, 2018.WATCH, JUDICIAL. 2019. “Census Bureau Still Hiring Felons, Child Sex Offenders Pass Background Check.” Legal. Judicial Watch. December 17, 2019.Ken Kingery. 2019. “Identifying the Epigenetic Fingerprints of Weapons of Mass Destruction.” Duke Pratt School of Engineering. September 12, 2019. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit walkinverse.substack.com/subscribe

Bloomberg News Cybersecurity Reporter Kartikay Mehrotra discusses the CEO of Colonial Pipeline Joseph Blount's grilling in front of a Senate Panel regarding the company's ransomware attack. Bloomberg Intelligence Commodity Strategist Mike McGlone discusses attending the “Woodstock of Bitcoin" and the digital currency in Miami last week. Bloomberg Intelligence Mandeep Singh on the massive Internet outage that affected popular websites and news outlets. Bloomberg News Healthcare reporter Robert Langreth on Biogen's FDA Victory Changes the Game for Alzheimer's Drugs. And we Drive to the Close with Eric Jackson, President of EMJ Capital as stocks close near records. Hosted by Carol Massar and Tim Stenovec. Producer: Paul Brennan Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Bloomberg News Cybersecurity Reporter Kartikay Mehrotra discusses the CEO of Colonial Pipeline Joseph Blount's grilling in front of a Senate Panel regarding the company's ransomware attack. Bloomberg Intelligence Commodity Strategist Mike McGlone discusses attending the “Woodstock of Bitcoin" and the digital currency in Miami last week. Bloomberg Intelligence Mandeep Singh on the massive Internet outage that affected popular websites and news outlets. Bloomberg News Healthcare reporter Robert Langreth on Biogen's FDA Victory Changes the Game for Alzheimer's Drugs. And we Drive to the Close with Eric Jackson, President of EMJ Capital as stocks close near records. Hosted by Carol Massar and Tim Stenovec. Producer: Paul Brennan

Just two months ago, the incredible performance of new vaccines from Moderna and Pfizer had people cheering for an imminent end to the pandemic. But an onslaught of fast-spreading and potentially dangerous mutations of the virus changed that. So now, even as pharma companies ramp up production in the early stages of a massive rollout, they are racing to retool their vaccine strategies. Robert Langreth reports that booster shots could give drugmakers a lucrative new revenue stream. 

Vaccines from Pfizer, Moderna and others will have the power to one day end the pandemic, or at least tame it—but only after 70 percent or more of the world’s population gets inoculated against Covid-19. So far, the rollout has been anything but smooth. Big drugstores say they’re ready to come to the rescue. Robert Langreth and Angelica Lavito describe the potentially massive vaccine infrastructure that the neighborhood pharmacy could provide.

Eight months into the pandemic, the coronavirus is on a rampage around the world. In Europe, a surge in cases has led to a new wave of lockdowns. The U.S. is entering its most dangerous period for the virus yet, and more than 10 million people have been infected. With Michelle Fay Cortez and Robert Langreth, we look back at how we got here, and ahead to what’s next for the outbreak.

Robert Langreth of Bloomberg Health Team joins Michael Calhoun talking about the Covid vaccine from Pfizer See omnystudio.com/listener for privacy information.

The race for a COVID-19 vaccine entered a new phase recently. Four different vaccine candidates, developed by Moderna, Pfizer, BionTech and Johnson & Johnson, entered final-stage trials, with two others close behind. But we won’t know exactly how these four vaccines work for months. Robert Langreth explains what we can, and, more importantly, can’t know about a vaccine developed at breakneck speed.

Coronavirus continues its terrifying rampage of large swaths of the country. But the Trump administration has made a point of mentioning that even while cases are rising, deaths are declining. That disconnect is, he says, proof the Covid-19 pandemic is under control. But the mismatch could be an anomaly caused by quirks in how deaths data is collected and reported. It's not necessarily a sign the coronavirus is becoming less lethal or easier to treat. Robert Langreth and Emma Court report that it’s too soon to know for sure that deaths are still declining.

The controversial drug is back in the news. In the early days of the pandemic, President Trump and some doctors touted it as an effective treatment. But studies soon discredited the treatment. Now, in an unexpected twist, some research papers dismissing the drug have also been thrown in doubt. So how useful is Hydroxychloroquine and how reliable are the reviews we rely on to assess a drug's safety? Laura Carlson speaks to Bloomberg reporters Michelle Cortez and Robert Langreth for answers.

When Covid-19 hit, Gilead Sciences Inc. had enough of its experimental drug remdesivir ready to test and start manufacturing it at a larger scale. That's because it had started stockpiling not just the drug, but its ingredients, at the first hint there may be a new coronavirus. Robert Langreth reports on why the company was able to act early to prepare for a pandemic when so many businesses and institutions did not.

Scientists are facing unparalleled pressure to provide information about the coronavirus as quickly as possible. And when every day brings forth new data, what was clear one day may be confusing the next. Guidance has shifted rapidly about the benefits of wearing masks, how the virus spreads, and even the efficacy of promising new drugs like Remdesivir. Science doesn't usually move this fast. Michelle Fay Cortez and Robert Langreth report on what happens when the slow and steady process of research, peer review, and the traditional publication process hits warp speed?

In this thank you bonus episode, members of our community - including a doctor on the frontlines of COVID-19 who has been forced to take a pay cut during a pandemic - update us on how their COVIDpocalyspe is going as Jen thanks all the producers who make Congressional Dish possible.  Please Support Congressional Dish – Quick Links Click here to contribute monthly or a lump sum via PayPal Click here to support Congressional Dish for each episode via Patreon Send Zelle payments to: Donation@congressionaldish.com Send Venmo payments to: @Jennifer-Briney Send Cash App payments to: $CongressionalDish or Donation@congressionaldish.com Use your bank’s online bill pay function to mail contributions to: 5753 Hwy 85 North, Number 4576, Crestview, FL 32536 Please make checks payable to Congressional Dish Thank you for supporting truly independent media! Articles/Documents Article: COVID-19 'Liberate' Groups Are the Same Ones Pushing Climate Denial By Steve Horn, Desmog, April 20, 2020 Article: Two-Thirds of Severe Covid-19 Cases Improved on Gilead Drug By Michelle Fay Cortez, Robert Langreth, and Jason Gale, Bloomberg, April 10, 2020 Article: Sen. Richard Burr, who sold stock before pandemic, voted in 2012 against banning insider trading for Congress By Timothy Bella, The Washington Post, March 20, 2020 Additional Resources YouTube Video: Krystal Ball: Plutocrat Senators profit while fleecing the public, The Hill Legislative Notice: H.R. 6172 – USA FREEDOM REAUTHORIZATION ACT, Senate RPC, Senator Roy Blunt, Chairman H.R.6172 - USA FREEDOM Reauthorization Act of 2020, Congress.gov Cover Art Design by Only Child Imaginations Music Presented in This Episode Intro & Exit: Tired of Being Lied To by David Ippolito (found on Music Alley by mevio)

(00:00-09:16): Jo Yurcaba writes “No, we actually *don’t* have a ton of free time right now. Why we need to stop perpetuating that myth” in Well and Good magazine. Brian and Ian respond to the premise of “having more time” but also how having to adapt to the circumstances is posing more challenges and taking up more time. (09:16-18:33): Willie Geist responds in a tweet to the Washington Post article “Rallies against stay-at-home orders grow as Trump sides with protesters”. (18:33-27:48): Robert Langreth writes “Americans Are Poisoning Themselves in Their Rush to Fight Virus” in Bloomberg. Brian and Ian discuss the hastey nature of the American’s response and treatment of the disease. (27:48-37:48): We continue to listen to part two of a series called “Meaning Making in the Midst of Pandemic” from Pastor John Perrine. The second part is called “The Mic Drop of Moses”. (38:45-49:45): How are we embracing the chaotic side of Zoom? Ever since we were restricted from meeting with one another, Zoom and other multimedia communication has skyrocketed. Brian and Ian talk about different ways we are going about meetings, social gatherings, even dating using this technology. (49:45-1:00:12): We are joined by father and son author duo Brian and Jeff Becker. They co-wrote the book “Tender Lions”. They are here to provide their perspective on dealing with stress during the COVID-19 pandemic. They say there isn’t a single person in the world right now who isn’t impacted by this virus; whether that is financial, physically, emotionally, etc. (1:00:12-1:10:43): Jim Denison writes “COVID-19 Is Not God’s Judgment” in Christianity Today. How can we know God isn’t acting now as he acted against Pharaoh? Brian and Ian reflect on God’s presence in the midst of this, and how to answer concerns to this predicament. (1:11:46-1:19:03): Brian and Ian’s “Weird Stuff We Found on the Internet”See omnystudio.com/listener for privacy information.

Robert Langreth, Bloomberg health care reporter, on Man vs. Microbe. Elisa Martinuzzi, Bloomberg Opinion finance columnist, on Credit Suisse ousting CEO Thiam in a boardroom clash. Tom Gimbel, CEO of global staffing company LaSalle Network, on how the job market is still seeing high demand. Mary Schlangenstein, U.S. Airlines reporter for Bloomberg, on JetBlue Founder Neeleman’s new low-cost airline, Breeze Airways.

Carol is joined by journalist and podcast host Ted Canova and they speak to Erik Davidson, CIO for Wells Fargo Private Bank, on the investor optimism. Robert Langreth, Bloomberg News Health Care Reporter, talks about Amazon acquiring online pharmacy PillPack. Bloomberg Stocks Editor Dave Wilson shares his Chart of the Day on emerging markets. Selina Wang, Bloomberg Global Technology Reporter, discusses Alibaba making fewer U.S. deals in light of the Trump administration's crackdown on Chinese investment in U.S. companies.  We Drive to the Close with Jim Lowell, CIO at Adviser Investments. And finally General Mills CEO Jeff Harmening discusses their acquisition for pet food company Blue Buffalo. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Carol is joined by journalist and podcast host Ted Canova and they speak to Erik Davidson, CIO for Wells Fargo Private Bank, on the investor optimism. Robert Langreth, Bloomberg News Health Care Reporter, talks about Amazon acquiring online pharmacy PillPack. Bloomberg Stocks Editor Dave Wilson shares his Chart of the Day on emerging markets. Selina Wang, Bloomberg Global Technology Reporter, discusses Alibaba making fewer U.S. deals in light of the Trump administration’s crackdown on Chinese investment in U.S. companies.  We Drive to the Close with Jim Lowell, CIO at Adviser Investments. And finally General Mills CEO Jeff Harmening discusses their acquisition for pet food company Blue Buffalo.

Damian Sassower, Fixed Income Strategist for Bloomberg Intelligence, on the lack of bids for emerging market debt. VolitionRX Group CEO Cameron Reynolds on developing a colon cancer test that could soon mean no more invasive colonoscopies. Kristina Swallow, President of American Society of Civil Engineers, to discuss President Trump's infrastructure plan and what improvements needs to be made. Robert Langreth, senior health care reporter for Bloomberg, on Amazon’s push into the health industry supply chain, angling to become the go-to source for basic medical supplies.

Ed Hammond is joined by senior Bloomberg healthcare reporter Robert Langreth to discuss CVS' $68 billion takeover of health insurer Aetna. How will the US regulators respond to this latest vertical merger and how much of CVS' push into the complex insurance market is driven by the threat of Amazon entering the pharmacy market?

Robert Langreth, reporter for Bloomberg News, discusses an IRS probe into the tax-exempt status of the Chronic Disease Fund, a patient-assistance charity funded by pharmaceutical companies. Critics say it allows pharmaceutical companies to help patients pay for expensive drugs. He speaks with Greg Stohr and June Grasso on Bloomberg Radio's "Bloomberg Law."

Robert Langreth, reporter for Bloomberg News, discusses an IRS probe into the tax-exempt status of the Chronic Disease Fund, a patient-assistance charity funded by pharmaceutical companies. Critics say it allows pharmaceutical companies to help patients pay for expensive drugs. He speaks with Greg Stohr and June Grasso on Bloomberg Radio's "Bloomberg Law." Learn more about your ad-choices at https://www.iheartpodcastnetwork.com